How OncoBEAM™ works

Detecting tumor mutations in blood

OncoBEAM™ detects tumor mutations from a simple blood draw

Tumor cells release mutant gene fragments into circulation, providing highly specific markers that can be used to detect tumor activity. The number of circulating tumor DNA (ctDNA) fragments, however, can be very small, making ctDNA difficult to detect.

OncoBEAM™ overcomes this difficulty thanks to the highly-sensitive BEAMing technology, which combines digital polymerase chain reactions (PCR) with magnetic beads and flow cytometry to deliver clinical assays for the accurate detection of ctDNA.

Watch BEAMing technology in action

 

DNA Isolation

The BEAMing process deconstructed

1. DNA Isolation

The BEAMing process begins with the isolation of circulating DNA from a patient’s blood or plasma sample.

Pre-Amplification

2. Pre-Amplification

Target regions of the purified DNA undergo a pre-amplification step with conventional PCR utilizing primers of known sequences to amplify the genetic regions of interest.

Emulsion PCR

3. Emulsion PCR

These amplified DNA fragments are then compartmentalized in a water-in-oil emulsion consisting of millions of individual water droplets, each of which containing one target DNA fragment and one magnetic beads. During the digital emulsion PCR process, each single DNA fragment is amplified utilizing primers covalently bound to the bead surface resulting in the conversion of a single DNA fragment into a DNA-covered bead.

Hybridization

4. Hybridization

Following emulsion PCR, the emulsion is broken and the beads are magnetically purified. Fluorescent probes are then attached (hybridized) to the DNA fragments on the beads to distinguish between wild-type and mutant DNA fragments. One fluorescent probe binds specifically to the wild-type DNA and the other probe is specific for mutant DNA.

Flow Cytometry

5. Flow Cytometry

Each individual fluorescently labelled bead is analyzed in a flow cytometer resulting in the precise separation of beads carrying mutant from those carrying wild-type DNA. The ratio of wild-type and mutant beads accurately represents the ratio of wild-type and mutant DNA in the patient’s blood sample.

Proven to deliver accurate results

Use of OncoBEAM™ and BEAMing technology for the testing of various mutations related to non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma has been studied in multiple clinical studies.

Review studies

Get a real-time snapshot of your patient's tumor

OncoBEAM™ for NSCLC

Test for 18 EGFR, KRAS, and BRAF mutations

OncoBEAM™ for CRC

Test for 34 KRAS, NRAS, and BRAF mutations

OncoBEAM™ for Melanoma

Test for 9 NRAS and BRAF mutations